Huntington Disease
A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
Drugs by status
Approved for this indication (2)
Phase 4 trials (1)
Phase 3 trials (20)
Phase 2 trials (42)
- Mardepodect
- mavoglurant
- anx005
- acetylcysteine
- bn82451b
- citalopram
- valproic acid
- cannabidiol
- amantadine
- ionis httrx
- laquinimod
- lithium
- Branaplam
- dronabinol
- oms643762
- pbt2
- sodium phenylbutyrate
- risperidone
- sen0014196
- srx-246
- triheptanoin
- nicotinamide
- thiamine
- vx15/2503
- biotin
- l-epigallocatechin
- bupropion
- autologous mononuclear stem cell
- atomoxetine
- fenofibrate
- +12 more
Phase 1 trials (21)
Organizations
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (23)
- Auspex Pharmaceuticals
- Roche
- Medivation
- Pfizer
- Sanofi
- Neurocrine Biosciences
- NeuroSearch A/S
- Amarin
- National Center for Complementary and Integrative Health (NCCIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Harvard University
- Huntington Study Group
- Johns Hopkins University
- University of Rochester
- University of British Columbia
- University of California, San Francisco
- Food and Drug Administration
- Azidus
- University of Paris
- Cures Within Reach
- University of Antwerp
- Cellavita Pesquisa Científica Ltda
- Prilenia
Organization Involved with Phase 2 Indications (38)
- Eli Lilly
- Ipsen
- Novartis
- Azevan Pharmaceuticals
- EIP Pharma, LLC
- GW Pharmaceuticals Ltd.
- Ionis Pharmaceuticals, Inc.
- Omeros Corporation
- SOM Biotech SL
- Siena Biotech S.p.A.
- Vaccinex Inc.
- National Institutes of Health (NIH)
- Institut National de la Santé Et de la Recherche Médicale, France
- Universidad Complutense de Madrid
- University of Iowa
- University of Kansas
- Mayo Clinic
- Columbia University
- University of California, Irvine
- University of Ulm
- Feinstein Institute for Medical Research
- University of Munster
- Annexon
- Ultragenyx Inc.
- Alterity Therapeutics
- Chaitanya Hospital
- Ruhr University Bochum
- European Huntington's Disease Network
- University of Alabama, Birmingham
- Humboldt University
- +8 more
Organization Involved with Phase 1 Indications (18)
- GlaxoSmithKline
- Paloma Pharmaceuticals, Inc.
- Sage Therapeutics
- Chong Kun Dang Pharmaceutical
- CHDI Foundation, Inc.
- Georgetown University
- Institute for Neurodegenerative Disorders
- Oregon Health and Science University
- Seoul National University
- Wake Forest University
- Zhejiang University
- Covance
- Karolinska Institute
- CIM Sant Pau
- University of Barcelona
- Kaneka Corporation
- Palo Biofarma, S.L
- Fundacion Huntington Puerto Rico
Organization Involved with Other Experimental Indications (1)